• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr David Eagle: Progress in Hematology/Oncology Is Not Without Its Difficulties

Video

For all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care, explained David A. Eagle, MD, New York Cancer & Blood Specialists.

David A. Eagle, MD, chair of legislative affairs and patient advocacy at New York Cancer & Blood Specialists, explains how even progress has its drawbacks, as for all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care.

Transcript

In the past 2-plus decades, what have been some of the biggest advancements in hematology/oncology?

The biggest advantages have clearly been on the scientific level: immunotherapy, targeted therapy. It begins with oncogenes, where we finally figured out, really, what makes a cancer a cancer. That’s clearly been the biggest progress in oncology. The problem is, as we talked about earlier, that that’s creating a natural tension between what we can do for patients and how we actually pay for that care.

Related Videos
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Andrew Kuykendall, MD, Moffitt Cancer Center
Anna Mueller, MD, Mount Sinai
Marc Humbert, MD, PhD
Susan Cantrell, CEO of AMCP
John Ostrominski, MD
John Buse, MD, PhD
Marc P. Bonaca, MD, MPH
Christian T. Ruff, MD, MPH
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.